ZOETIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 164.9 USD | -2.10% |
|
+4.05% | -16.44% |
| 05-08 | HSBC Adjusts Price Target on Zoetis to $225 From $230 | MT |
| 05-06 | BNP Paribas Exane Adjusts Price Target on Zoetis to $232 From $237 | MT |
ETFs positioned on Zoetis Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 6 M€ | +3.89% | ||
| 0.05% | 0 M€ | +3.03% | - | |
| 0.03% | 0 M€ | +0.73% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | +3.16% | - | |
| 0.02% | 0 M€ | +0.54% | - | |
| 0.02% | 6 M€ | -4.26% | - | |
| 0.02% | 0 M€ | +3.22% | - | |
| 0.01% | 0 M€ | -1.48% | - | |
| 0.02% | 0 M€ | +3.45% | - | |
| 6.85% | 0 M€ | +5.94% | - |
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:
- pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%);
- livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%);
- other (1.1%).
Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%).
At the end of 2022, the group has 29 production sites worldwide.
The United States accounts for 53.4% of net sales.
Sector
Pharmaceuticals
Calendar
22/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
164.9
USD
Average target price
211
USD
Spread / Average Target
+27.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.44% | 76.86B | |
| +13.36% | 6.66B | |
| +26.88% | 3.78B | |
| -0.42% | 3.14B | |
| +9.80% | 1.59B | |
| -11.98% | 1.43B | |
| -23.69% | 1.28B | |
| -7.23% | 1.22B | |
| -7.75% | 1.2B | |
| +9.76% | 1.09B |
- Stock Market
- Equities
- ZTS Stock
- Funds and ETFs Zoetis Inc.
